Caribou Biosciences vs Lineage Cell Therapeutics
CRBU and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRBU and LCTX compare
Lineage Cell Therapeutics is the larger company, worth 5.3 times as much as Caribou Biosciences ($201M against $37.8M).
Lineage Cell Therapeutics grew revenue faster over the last twelve months (19.9% versus 10.0% for Caribou Biosciences).
Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of −247% compared with −1030% at Caribou Biosciences.
Caribou Biosciences scores higher on the StockData Score (9 against 8 for Lineage Cell Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRBU | LCTX |
|---|---|---|
| Size and price | ||
| Market cap | $37.8M | $201M |
| Share price | $0.353 | $0.795 |
| Change, 1 year | −82.2% | −55.8% |
| Change, 5 years | −98.0% | −60.0% |
| Beta (5Y) | 1.36 | 1.21 |
| Employees | 97 | 77 |
| StockData Score | ||
| Total score | 9 (better) | 8 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 3.8× (better) | 15.4× |
| P/B | 0.4× (better) | 3.3× |
| FCF yield | −253% | −12.1% (better) |
| Fair value | $1.29 | $0.657 |
| Margin of safety | 72.6% (better) | −21.0% |
| Growth | ||
| Revenue growth (TTM) | 10.0% | 19.9% (better) |
| Revenue growth, 5Y average | −2.0% | 51.5% (better) |
| Profitability | ||
| Operating margin | −1091% | −205% (better) |
| Net margin | −1030% | −247% (better) |
| FCF margin | −954% | −186% (better) |
| Return on equity | −78.3% | −59.0% (better) |
| Return on invested capital | – | −262% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 6.49 | 6.61 (better) |
| Altman Z-score | −7.46 | −3.80 (better) |
| Piotroski F-score | 2 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −64.0% | – |
| Shareholder yield | −64.0% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 45.5% | 46.1% |
| Held by insiders | 5.7% | 74.4% |
| Insider net buying, 12 months | −$47.5K | $24.4K (better) |
| Short interest, % of float | 14.7% | 37.7% |
Go deeper
- CRBU stock overview
- CRBU income statement
- CRBU valuation and score
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.